Capital Fund Management (CFM)
SAGE

Capital Fund Management (CFM)’s Sage Therapeutics SAGE Stock Holding History

Capital Fund Management (CFM)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-196,543
Closed -$2.13M – 2130
2024
Q2 		$2.13M Buy
196,543
+63,391
+48% +$812K 0.01% 1354
2024
Q1 		$2.5M Buy
133,152
+60,246
+83% +$1.39M 0.01% 1349
2023
Q4 		$1.58M Buy
72,906
+46,894
+180% +$929K ﹤0.01% 1642
2023
Q3 		$535K Buy
26,012
+5,981
+30% +$173K ﹤0.01% 1787
2023
Q2 		$942K Sell
20,031
-1,728
-8% -$86K ﹤0.01% 1417
2023
Q1 		$913K Buy
21,759
+5,270
+32% +$227K ﹤0.01% 1298
2022
Q4 		$629K Buy
16,489
+5,340
+48% +$204K ﹤0.01% 1228
2022
Q3 		$437K Sell
11,149
-23,011
-67% -$889K ﹤0.01% 1297
2022
Q2 		$1.1M Sell
34,160
-22,402
-40% -$751K 0.01% 1042
2022
Q1 		$1.87M Sell
56,562
-19,761
-26% -$743K 0.02% 978
2021
Q4 		$3.25M Buy
76,323
+10,649
+16% +$446K 0.02% 814
2021
Q3 		$2.91M Buy
65,674
+12,363
+23% +$567K 0.02% 780
2021
Q2 		$3.03M Sell
53,311
-10,019
-16% -$708K 0.02% 773
2021
Q1 		$4.74M Buy
63,330
+52,590
+490% +$4.31M 0.05% 443
2020
Q4 		$929K Buy
+10,740
New +$792K 0.01% 1011
2020
Q2 		– Sell
-16,161
Closed -$587K – 1494
2020
Q1 		$464K Buy
+16,161
New +$936K 0.01% 1052
2019
Q2 		– Sell
-1,297
Closed -$206K – 1878
2019
Q1 		$206K Buy
+1,297
New +$188K ﹤0.01% 1583
2018
Q1 		– Sell
-3,065
Closed -$505K – 2138
2017
Q4 		$505K Buy
+3,065
New +$297K ﹤0.01% 1444

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capital Fund Management (CFM)'s SAGE Position: Q3 2024 in Review

Capital Fund Management (CFM) sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 196,543 shares — an estimated $2.13M sold.

Capital Fund Management (CFM) first reported a position in SAGE in Q4 2017 and held it in 18 quarters. The position peaked at $4.74M in Q1 2021. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Capital Fund Management (CFM) reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 196,543 Sage Therapeutics shares in Q3 2024, an estimated $2.13M.
  • Capital Fund Management (CFM) first reported a position in Sage Therapeutics in Q4 2017 and held it in 18 quarters.
  • Capital Fund Management (CFM)'s Sage Therapeutics position peaked at $4.74M in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2024, filed 13 Nov 2024.